Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first patient in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime. The trial will...
Dermira’s (NASDAQ:DERM) lebrikizumab received FDA fast track designation for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13, which is...
Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present two posters at the HEP DART 2019, frontiers in drug development for hepatology, including viral hepatitis, NASH and co-infections meeting. The presentations...
ObsEva’s (NASDAQ:OBSV) Phase 3 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids met its primary and secondary endpoints. The U.S. trial enrolled 535 women to evaluate the...
The FDA removed its clinical hold on Abeona Therapeutics’ (NASDAQ:ABEO) Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The hold was removed following...
Closely-held RecoveryOne, formerly Trainer Rx, which is focused on enabling patient recovery from musculoskeletal (MSK) conditions, is raising $12-million in a round led by Cigna Ventures. The company says the financing...
According to a number of trade media reports, Profound Medical’s (NASDAQ:PROF; TSX:PRN) recently 510(k)-cleared TULSA-PRO system received high marks at the Radiology Society of North America (RSNA) annual meeting. TULSA...
Omeros (NASDAQ:OMER) reported positive data from its pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). HSCT-TMA occurs when...
Rhythm Pharmaceuticals (NASDAQ:RYTM) completed enrollment of the pivotal cohort in its Phase 3 trial of setmelanotide for the treatment of insatiable hunger and severe obesity in Bardet-Biedl syndrome (BBS) or Alström...
Anavex Life Sciences (NASDAQ:AVXL) presented interim two-year data from its Phase 2a extension study of ANAVEX2-73 in Alzheimer’s disease (AD) patients at the 2019 clinical trials on AD conference. ANAVEX2-73 is...
Aptinyx (NASDAQ:APTX) launched a Phase 2 study of NYX-458 for the treatment of mild cognitive impairment associated with Parkinson’s disease (PD). NYX-458 is an n-methyl-d-aspartate, or NMDA, receptor modulator. The 135...
Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its Phase 2 clinical trial evaluating zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). IMNM is an autoimmune disease characterized...
Closely-held Hummingbird Bioscience raised $19-million in a Series B financing round co-led by Mirae Asset Venture Investment and GNTech Venture Capital. Existing investors Heritas Capital and Seeds Capital also...
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...
Aldeyra Therapeutics (NASDAQ:ALDX) reported positive topline results from the first part of its adaptive Phase 3 trial of topical ocular reproxalap for the treatment of dry eye disease. Part 1 of the study assessed...
Hepion Pharmaceuticals’ (NASDAQ:HEPA) Drs. Robert Foster, CEO; Daren Ure, CSO; Daniel Trepanier, SVP drug development; and Patrick Mayo, SVP clinical pharmacology have been appointed adjunct professors by the University...
Healthcare-only investor relations and capital markets advisory firm, Kilmer Lucas, unveiled the lineup for its first annual BioTuesdays Pre-JPM Virtual Conference, beginning at 11:00 am ET on Dec. 10, 2019...
Kane Biotech (TSX-V:KNE) was selected to receive an award of up to about $3.4-million from an unnamed government agency for the continuing clinical development of DispersinB to treat biofilm mediated antimicrobial...
Evofem Biosciences (NASDAQ:EVFM) announced positive topline results from its Phase 2b trial evaluating Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met its primary and secondary...
Phathom Pharmaceuticals (NASDAQ:PHAT) launched its Phase 3 trial of vonoprazan for the healing and healing maintenance of erosive esophagitis (EE). EE is a type of gastroesophageal reflux disease, or GERD, caused by...
Kamada (NASDAQ, TASE:KMDA) agreed to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, pending approval of the Israeli Ministry of Health (IMOH). Alvotech’s pipeline includes biosimilar...
Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 2 study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in patients who are stable on an antipsychotic medication. CTP-692 is a deuterium...